By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Bavarian Nordic Transactions in Connection with Share Buy-Back Program
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > Bavarian Nordic Transactions in Connection with Share Buy-Back Program
Bavarian Nordic  Transactions in Connection with Share Buy-Back Program
Health

Bavarian Nordic Transactions in Connection with Share Buy-Back Program

GlobeNews Wire
Last updated: 08/06/2026 2:39 PM
GlobeNews Wire
Published: 08/06/2026
Share
SHARE

COPENHAGEN, Denmark, June 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from June 2, 2026 to July 10, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.

Since initiation of the program, the following transactions have been made by Nordea on behalf of Bavarian Nordic:

  Number of shares Average purchase price, DKK Transaction value, DKK
June 2, 2026  31,294 183.45  5,740,887
June 3, 2026  18,527 180.55  3,344,996
June 4, 2026  348 179.97  62,631
Accumulated under the program 50,169 182.35 9,148,515

The details for each transaction made under the share repurchase program are published on bavarian-nordic.com.

Following these transactions, Bavarian Nordic holds a total of 2,788,153 treasury shares, corresponding to 3.52% of the Company’s share capital.

About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit www.bavarian-nordic.com

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact investors:
Europe: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel. +45 33 26 83 83
US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600

Contact media:
Nicole Seroff, Vice President Corporate Affairs, nise@bavarian-nordic.com, Tel: +45 53 88 06 03

Company Announcement no. 27 / 2026

  • Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
  • Appendix with detailed transaction data
Vita Smart Cup Massager Claims Evaluated: 2026 Report on Suction Therapy, Red Light Technology, and What Consumers Should Know Before Buying
ENA Respiratory Successfully Completes First Part of Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
Press release: Transparency Notification from Shareholder
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
TAGGED:Copenhagen:BAVADK0015998017MyWeb
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Team Adventure X Arunachal Pradesh Clinches Runner-Up at the Rally of Himalayas
News

Team Adventure X Arunachal Pradesh Clinches Runner-Up at the Rally of Himalayas

15/10/2025
air cargo India Marks its 11th Edition as transport logistic India Debuts in Mumbai
Ford Foundation Announces Heather Gerken as New President
India’s Growth Moves Beyond Metros: Dun & Bradstreet’s City Vitality Index Maps New Urban Powerhouses
Defeating the “Cold Chain” Barrier: Bio Usawa and Nanoly Bioscience Announce Strategic $500 Million Licensing Agreement for Breakthrough DynaShield Technology
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?